Carl Byrnes
Stock Analyst at Northland Capital Markets
(2.43)
# 2,397
Out of 4,893 analysts
23
Total ratings
50%
Success rate
12.81%
Average return
Main Sectors:
Stocks Rated by Carl Byrnes
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BLFS BioLife Solutions | Maintains: Outperform | $28 → $31 | $22.86 | +35.64% | 2 | Jan 8, 2025 | |
| TLSI TriSalus Life Sciences | Initiates: Outperform | $13 | $4.99 | +150.50% | 1 | Oct 25, 2024 | |
| BWAY BrainsWay | Maintains: Outperform | $11 → $13 | $12.52 | -0.16% | 3 | Oct 3, 2024 | |
| MDAI Spectral AI | Initiates: Outperform | $6 | $3.10 | +93.55% | 1 | Aug 12, 2024 | |
| COCH Envoy Medical | Initiates: Outperform | n/a | $1.45 | - | 1 | Dec 21, 2023 | |
| AMRN Amarin Corporation | Maintains: Market Perform | $40 → $25 | $17.18 | +45.52% | 1 | Jul 19, 2023 | |
| CDIO Cardio Diagnostics Holdings | Initiates: Outperform | $240 | $4.21 | +5,600.71% | 1 | May 22, 2023 | |
| VTVT vTv Therapeutics | Maintains: Outperform | $60 → $80 | $17.40 | +359.77% | 4 | Aug 17, 2022 | |
| MDXG MiMedx Group | Initiates: Outperform | $23 | $6.93 | +231.89% | 3 | Jul 26, 2021 | |
| ESPR Esperion Therapeutics | Maintains: Market Perform | $30 → $24 | $1.23 | +1,859.18% | 4 | May 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $2,000 | $2.28 | +87,619.30% | 1 | Oct 22, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $2.23 | - | 1 | Sep 27, 2017 |
BioLife Solutions
Jan 8, 2025
Maintains: Outperform
Price Target: $28 → $31
Current: $22.86
Upside: +35.64%
TriSalus Life Sciences
Oct 25, 2024
Initiates: Outperform
Price Target: $13
Current: $4.99
Upside: +150.50%
BrainsWay
Oct 3, 2024
Maintains: Outperform
Price Target: $11 → $13
Current: $12.52
Upside: -0.16%
Spectral AI
Aug 12, 2024
Initiates: Outperform
Price Target: $6
Current: $3.10
Upside: +93.55%
Envoy Medical
Dec 21, 2023
Initiates: Outperform
Price Target: n/a
Current: $1.45
Upside: -
Amarin Corporation
Jul 19, 2023
Maintains: Market Perform
Price Target: $40 → $25
Current: $17.18
Upside: +45.52%
Cardio Diagnostics Holdings
May 22, 2023
Initiates: Outperform
Price Target: $240
Current: $4.21
Upside: +5,600.71%
vTv Therapeutics
Aug 17, 2022
Maintains: Outperform
Price Target: $60 → $80
Current: $17.40
Upside: +359.77%
MiMedx Group
Jul 26, 2021
Initiates: Outperform
Price Target: $23
Current: $6.93
Upside: +231.89%
Esperion Therapeutics
May 5, 2021
Maintains: Market Perform
Price Target: $30 → $24
Current: $1.23
Upside: +1,859.18%
Oct 22, 2018
Initiates: Outperform
Price Target: $2,000
Current: $2.28
Upside: +87,619.30%
Sep 27, 2017
Initiates: Outperform
Price Target: n/a
Current: $2.23
Upside: -